Novel use of Etonogestrel (ETN) Subdermal Implant (SDI) in adolescents and reproductive age group women with endometriosis and its comparison with Levonogestrel Intra-Uterine System (LNG-IUS) A non-inferiority prospective pilot study

This project aims to explore the effectiveness of Etonogestrel Subdermal Implant (ETN-SDI) as a treatment for endometriosis-related pain in adolescent and reproductive-age women. Endometriosis, which affects 10-15% of women, often causes significant pelvic pain, dysmenorrhea, and infertility. Currently, available treatments, like combined oral contraceptives (COCs) and LNG-IUS (Levonorgestrel Intra-Uterine System), have limitations, especially in adolescent populations. ETN-SDI, a long-acting contraceptive, has shown promise in reducing pain associated with endometriosis and may offer additional benefits as a reversible contraceptive.

The study will compare the efficacy of ETN-SDI and LNG-IUS in reducing endometriosis pain, using a non-inferiority prospective trial with 100 participants. It will also examine factors like acceptability, quality of life, bleeding patterns, and biomarkers such as CA-125 and BMD. Expected outcomes include ETN-SDI as a safe, cost-effective, long-term treatment for endometriosis and an effective contraceptive option. The study could have significant implications for adolescent health by expanding treatment options and addressing both pain and contraception needs in this population.